Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

What Was Tested

Researchers studied PT-141 (Bremelanotide) and Alpha-MSH in this randomized controlled trial publication.

ClinicalTrials.gov, NCT02333071 (study 301) and NCT02338960 (study 302).

Who Took Part

PubMed indexes the participants as adults, women only.

Patients were randomized 1:1 to 24 weeks of treatment with bremelanotide or placebo.

Sample size was estimated based on simulations from key endpoints in patients with hypoactive sexual desire disorder from a prior trial.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this PT-141 (Bremelanotide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind PT-141 (Bremelanotide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the PT-141 (Bremelanotide) group a baseline to be compared against.

Running at several centres spread the PT-141 (Bremelanotide) study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Central Nervous System Agents, Libido, Peptides, Cyclic, Premenopause, Psychological Distress, Receptor, Melanocortin, Type 3 and Receptor, Melanocortin, Type 4.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of PT-141 (Bremelanotide) and Alpha-MSH.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Obstetrics and gynecology), a journal based in United States.

More context: the PT-141 (Bremelanotide) compound page and the Alpha-MSH compound page, all human trials.